Why AdaptHealth Stock Plummeted This Week
AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.
How this was made
The 30-second read
Why it matters
Q2 underperformance plus a large downward guidance reset (sales, EBITDA, and FCF) is a clear catalyst for estimate cuts and multiple compression, making the move actionable for traders managing near-term risk.
Market read
This is a guidance-driven repricing story with quantified misses and a substantial reduction in full-year financial targets.
What to watch
The article attributes the guidance reduction partly to discontinuing the Diabetes Health business and shifting to continuing operations; traders may want to separate continuing-ops performance from discontinued-unit effects when modeling future margins and FCF.
Background
The article frames AdaptHealth’s selloff as a direct reaction to its Aug. 4 Q2 earnings release and subsequent guidance revisions.
Ticker impact
AdaptHealth shares fell sharply after Q2 results missed expectations and the company cut full-year sales, EBITDA, and free cash flow guidance.
Bearish bias for the next several sessions as traders reprice the guidance cut and margin/FCF trajectory.
The article cites concrete, time-specific datapoints: Q2 EPS loss of $1.07 vs $0.15 expected, sales $740.3M below forecast, and major downward revisions to sales ($2.85B-$2.89B vs prior $3.45B-$3.52B) plus EBITDA and FCF ranges.
Market effects
Weak results and guidance cuts in a healthcare services model can pressure sentiment toward similar digital health and care-delivery platforms.
Limited; primarily company-specific repricing.
Low; no cross-border deal or macro linkage described.
Counterpoint
The user-growth figure (myApp registered users up ~56% YoY) could indicate underlying demand, and the guidance cut may reflect accounting/portfolio changes tied to discontinued Diabetes Health rather than core execution failure.
Key entities
- companyAdaptHealth
NASDAQ-listed healthcare services company whose Q2 results and forward guidance drove a steep weekly decline.
